Nothing Special   »   [go: up one dir, main page]

DE69722663D1 - Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität - Google Patents

Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität

Info

Publication number
DE69722663D1
DE69722663D1 DE69722663T DE69722663T DE69722663D1 DE 69722663 D1 DE69722663 D1 DE 69722663D1 DE 69722663 T DE69722663 T DE 69722663T DE 69722663 T DE69722663 T DE 69722663T DE 69722663 D1 DE69722663 D1 DE 69722663D1
Authority
DE
Germany
Prior art keywords
interleukin
activity
control
sulfonyl
urine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69722663T
Other languages
English (en)
Other versions
DE69722663T2 (de
Inventor
Anthony Dombroski
Frederick Eggler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE69722663D1 publication Critical patent/DE69722663D1/de
Application granted granted Critical
Publication of DE69722663T2 publication Critical patent/DE69722663T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50—Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52—Y being a hetero atom
    • C07C311/54—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/60—Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69722663T 1997-01-29 1997-12-29 Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität Expired - Fee Related DE69722663T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3697997P 1997-01-29 1997-01-29
US36979P 1997-01-29
PCT/IB1997/001603 WO1998032733A1 (en) 1997-01-29 1997-12-29 Sulfonyl urea derivatives and their use in the control of interleukin-1 activity

Publications (2)

Publication Number Publication Date
DE69722663D1 true DE69722663D1 (de) 2003-07-10
DE69722663T2 DE69722663T2 (de) 2004-04-29

Family

ID=21891776

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69729762T Expired - Fee Related DE69729762T2 (de) 1997-01-29 1997-12-29 4-Substituiertes Furan-2-sulfonamid und dessen Verwendung in der Herstellung von Sulfonylharnstoff-Derivate
DE69722663T Expired - Fee Related DE69722663T2 (de) 1997-01-29 1997-12-29 Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69729762T Expired - Fee Related DE69729762T2 (de) 1997-01-29 1997-12-29 4-Substituiertes Furan-2-sulfonamid und dessen Verwendung in der Herstellung von Sulfonylharnstoff-Derivate

Country Status (40)

Country Link
US (2) US6166064A (de)
EP (1) EP0964849B1 (de)
JP (1) JP3573757B2 (de)
KR (1) KR100324058B1 (de)
CN (1) CN1127479C (de)
AP (1) AP929A (de)
AR (1) AR011093A1 (de)
AT (2) ATE270285T1 (de)
AU (1) AU723895B2 (de)
BG (1) BG103597A (de)
BR (1) BR9714328A (de)
CA (1) CA2279186C (de)
CO (1) CO4920230A1 (de)
CZ (1) CZ293173B6 (de)
DE (2) DE69729762T2 (de)
DK (2) DK1270565T3 (de)
DZ (1) DZ2407A1 (de)
EA (1) EA001803B1 (de)
ES (2) ES2198598T3 (de)
HR (1) HRP980045B1 (de)
HU (1) HUP0000567A3 (de)
ID (1) ID22223A (de)
IL (1) IL130855A0 (de)
IS (1) IS5099A (de)
MA (1) MA26468A1 (de)
NO (1) NO313279B1 (de)
NZ (1) NZ336248A (de)
OA (1) OA11079A (de)
PA (1) PA8444701A1 (de)
PE (1) PE57898A1 (de)
PL (1) PL335052A1 (de)
PT (2) PT1270565E (de)
SK (1) SK283679B6 (de)
TN (1) TNSN98017A1 (de)
TR (1) TR199901816T2 (de)
TW (1) TW515788B (de)
UY (1) UY24861A1 (de)
WO (1) WO1998032733A1 (de)
YU (1) YU33799A (de)
ZA (1) ZA98685B (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022984A (en) * 1998-07-27 2000-02-08 Pfizer Inc. Efficient synthesis of furan sulfonamide compounds useful in the synthesis of new IL-1 inhibitors
EP1526383A3 (de) * 1998-08-31 2005-11-16 Pfizer Products Inc. Diarylsulphonylharnstoff-Bindungsproteine
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
EP1214087A1 (de) * 1999-09-14 2002-06-19 Pfizer Products Inc. Behandlung mit kombinationen aus il1-ra und diarylsulfonylureaverbindungen
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
MEP32608A (en) 2001-06-26 2011-02-10 Amgen Fremont Inc Antibodies to opgl
WO2003024948A1 (en) 2001-09-14 2003-03-27 Bayer Pharmaceuticals Corporation Benzofuran and dihydrobenzofuran derivatives useful as beta-3 adrenoreceptor agonists
AU2002341321A1 (en) * 2001-11-30 2003-06-10 Pfizer Products Inc. Combination of an il-1/18 inhibitor with a tnf inhibitor for the treatment of inflammation
US20030131370A1 (en) * 2001-12-14 2003-07-10 Pfizer Inc. Disruption of the glutathione S-transferase-Omega-1 gene
EP1707205A2 (de) 2002-07-09 2006-10-04 Boehringer Ingelheim Pharma GmbH & Co. KG Pharazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege
CA2824167C (en) 2002-09-06 2018-09-25 Amgen Inc. Therapeutic human anti-il-1r1 monoclonal antibody
WO2004031777A1 (en) * 2002-10-03 2004-04-15 Pfizer Products Inc. Use of gst-omega-2 as a therapeutic target
NZ627505A (en) 2003-08-06 2016-01-29 Senomyx Inc Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
ME01763B (de) * 2004-03-23 2010-10-31 Dompe Farm Spa 2-phenylpropionsäurederivate und diese enthaltende pharmazeutische zusammensetzung
US20060045953A1 (en) * 2004-08-06 2006-03-02 Catherine Tachdjian Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
NZ560849A (en) 2005-02-04 2011-02-25 Senomyx Inc Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
WO2006090927A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の摂食亢進作用
US7208526B2 (en) * 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
AR055329A1 (es) 2005-06-15 2007-08-15 Senomyx Inc Amidas bis-aromaticas y sus usos como modificadores de sabor dulce, saborizantes, y realzadores de sabor
ES2640453T3 (es) 2006-04-21 2017-11-03 Senomyx, Inc. Procesos para preparar composiciones saborizantes sólidas
EP1992344A1 (de) 2007-05-18 2008-11-19 Institut Curie P38 Alpha als therapeutisches Target für Erkrankungen, die mit einer FGFR3- Mutation assoziiert sind
US7973051B2 (en) * 2007-11-30 2011-07-05 Hoffman-La Roche Inc. Aminothiazoles as FBPase inhibitors for diabetes
EP2919788A4 (de) 2012-11-14 2016-05-25 Univ Johns Hopkins Verfahren und zusammensetzungen zur behandlung von schizophrenie
US10385040B2 (en) 2014-08-12 2019-08-20 Loyola University Of Chicago Indoline sulfonamide inhibitors of DapE and NDM-1 and use of the same
RS60048B1 (sr) * 2015-02-16 2020-04-30 Univ Queensland Sulfoniluree i srodna jedinjenja i njihova upotreba
WO2016138473A1 (en) * 2015-02-26 2016-09-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inflammasome activation in myelodysplastic syndromes
FR3046933B1 (fr) 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
MX2018009840A (es) * 2016-02-16 2019-01-21 Univ Queensland Sulfonilureas y compuestos relacionados y sus usos.
MA44734A (fr) * 2016-04-18 2021-05-19 Novartis Ag Composés et compositions destinés au traitement d'états associés à une activité de nlrp
ES2927777T3 (es) 2016-04-18 2022-11-10 Novartis Ag Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP
EP3272739A1 (de) * 2016-07-20 2018-01-24 NodThera Limited Sulfonylharnstoff-derivate und ihre verwendung in der kontrole der interleukin-1-aktivität
US20220267260A1 (en) * 2016-11-29 2022-08-25 Epizyme, Inc. Compounds containing a sulfonic group as kat inhibitors
MY197636A (en) 2017-01-23 2023-06-29 Genentech Inc Chemical compounds as inhibitors of interleukin-1 activity
CA3059458A1 (en) * 2017-05-24 2018-11-29 The University Of Queensland Novel compounds and uses
EP3634951B8 (de) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Neuartige substituierte sulfoximinverbindungen
KR102669722B1 (ko) 2017-07-07 2024-05-29 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
WO2019008029A1 (en) 2017-07-07 2019-01-10 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
SG11201912166XA (en) 2017-07-24 2020-02-27 Novartis Inflammasome Research Inc Compounds and compositions for treating conditions associated with nlrp activity
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
RU2020110394A (ru) 2017-08-15 2022-01-20 Инфлазоум Лимитед Новые соединения сульфонамидкарбоксамидов
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
EP3668843A1 (de) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylharnstoffe und sulfonylthioharnstoffe als nlrp3-inhibitoren
WO2019043610A1 (en) 2017-08-31 2019-03-07 Cadila Healthcare Limited NEW SUBSTITUTED SULFONYLUREA DERIVATIVES
WO2019068772A1 (en) 2017-10-03 2019-04-11 Inflazome Limited NEW COMPOUNDS
US11718631B2 (en) 2017-10-17 2023-08-08 Novartis Ag Sulphonamides and compositions thereof for treating conditions associated with NLRP activity
AU2018363771A1 (en) 2017-11-09 2020-05-14 Inflazome Limited Novel sulfonamide carboxamide compounds
GB201721185D0 (en) 2017-12-18 2018-01-31 Nodthera Ltd Sulphonyl urea derivatives
CN108299256B (zh) * 2018-01-09 2019-09-10 武汉大学 一类2,3,4-三羟基苯磺酰胺衍生物及其制备方法和应用
EP3759090A1 (de) 2018-03-02 2021-01-06 Inflazome Limited Neuartige verbindungen
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
EP3759103A1 (de) 2018-03-02 2021-01-06 Inflazome Limited Neuartige verbindungen
US11834433B2 (en) 2018-03-02 2023-12-05 Inflazome Limited Compounds
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
EP3817817A1 (de) 2018-07-03 2021-05-12 Novartis AG Nlrp-modulatoren
MA53170A (fr) 2018-07-20 2021-05-26 F Hoffmann La Roche Sa Composés de sulfonylurée en tant qu'inhibiteurs de l'activité de l'interleukine 1
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
JP2022505525A (ja) * 2018-10-24 2022-01-14 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
EP3911631A4 (de) 2019-01-14 2022-09-28 Cadila Healthcare Limited Neuartige substituierte sulfonylharnstoffderivate
PT3983387T (pt) 2019-06-12 2024-07-10 Nodthera Ltd Derivados de sulfonilurea e seus usos
CN114008030A (zh) 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪
US20220313657A1 (en) * 2019-09-12 2022-10-06 Cadila Healthcare Limited Novel substituted sulfoximine derivatives
CN115768749B (zh) * 2020-06-11 2024-04-19 辰欣药业股份有限公司 二甲基亚磺酰亚胺衍生物
AU2021291065A1 (en) 2020-06-19 2022-12-15 Ac Immune Sa Dihydrooxazole and thiourea derivatives modulating the NLRP3 inflammasome pathway
WO2022022646A1 (zh) * 2020-07-29 2022-02-03 南京明德新药研发有限公司 含硒五元杂芳环化合物
JP2023540733A (ja) 2020-09-04 2023-09-26 ノッドセラ リミテッド アルキルオキサシクロアルキル部分を含むスルファモイル尿素誘導体およびその使用
ES2948511A1 (es) * 2021-09-08 2023-09-13 Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa Derivados de n-sulfonilureas y su uso terapeutico
WO2023098612A1 (zh) * 2021-12-03 2023-06-08 南京明德新药研发有限公司 二甲基亚磺酰亚胺衍生物的盐型及晶型
CN118541366A (zh) 2021-12-22 2024-08-23 Ac免疫有限公司 二氢噁唑衍生物化合物
IL313903A (en) * 2022-02-15 2024-08-01 Hoffmann La Roche Processes for the preparation of 1,2,3,5,6,7-HEXAHYDRO-S-INDACENE derivatives
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
WO2024013395A1 (en) 2022-07-14 2024-01-18 Ac Immune Sa Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway
US20240101563A1 (en) 2022-07-28 2024-03-28 Ac Immune Sa Novel compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4586950A (en) * 1982-05-31 1986-05-06 E. I. Du Pont De Nemours & Company Novel phenyl-substituted sulfonamides
US4780125A (en) * 1982-09-01 1988-10-25 Ciba-Geigy Corporation N-phenylsulfonyl-N'-triazinylureas
DE3927369A1 (de) * 1989-08-19 1991-02-21 Bayer Ag Substituierte n-(chinolin-2-yl-methoxy)benzyl-sulfonyl-harnstoffe
US5064851A (en) * 1990-07-24 1991-11-12 Pfizer Inc. 3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
US5254589A (en) * 1991-10-15 1993-10-19 Warner-Lambert Company Sulfonyl urea and carbamate ACAT inhibitors
DE4344957A1 (de) * 1993-12-30 1995-07-06 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Herstellungsverfahren und Verwendungsmöglichkeiten pharmazeutischer Präparate auf Basis dieser Verbindungen
CN1038679C (zh) * 1994-12-07 1998-06-10 南开大学 磺酰脲类化合物及其除草用途
HU226462B1 (en) * 1995-02-17 2008-12-29 Hoechst Ag Substituted benzol-sulfonyl-ureas and -thioureas, process for producing them, pharmaceutical compositions containing them, and their use
US6281240B1 (en) * 1997-04-10 2001-08-28 Eli Lilly And Company Diarylsulfonylureas for use in treating secretory diarrhea

Also Published As

Publication number Publication date
CZ293173B6 (cs) 2004-02-18
DE69729762T2 (de) 2005-07-14
ES2222426T3 (es) 2005-02-01
AU5234098A (en) 1998-08-18
EP0964849A1 (de) 1999-12-22
BG103597A (bg) 2000-02-29
DK0964849T3 (da) 2003-08-25
UY24861A1 (es) 2000-09-29
EA001803B1 (ru) 2001-08-27
EP0964849B1 (de) 2003-06-04
TR199901816T2 (xx) 1999-11-22
SK283679B6 (sk) 2003-11-04
JP2000511200A (ja) 2000-08-29
SK98299A3 (en) 2001-10-08
NO993658L (no) 1999-09-28
CA2279186A1 (en) 1998-07-30
EA199900603A1 (ru) 2000-02-28
IL130855A0 (en) 2001-01-28
ATE270285T1 (de) 2004-07-15
HUP0000567A2 (hu) 2000-10-28
AU723895B2 (en) 2000-09-07
IS5099A (is) 1999-06-29
KR100324058B1 (ko) 2002-02-16
ID22223A (id) 1999-09-16
ES2198598T3 (es) 2004-02-01
HRP980045A2 (en) 1999-06-30
HUP0000567A3 (en) 2002-10-28
PA8444701A1 (es) 2000-05-24
PL335052A1 (en) 2000-03-27
BR9714328A (pt) 2000-03-21
HRP980045B1 (en) 2002-10-31
US6433009B1 (en) 2002-08-13
AR011093A1 (es) 2000-08-02
TW515788B (en) 2003-01-01
NO313279B1 (no) 2002-09-09
YU33799A (sh) 2002-03-18
PT1270565E (pt) 2004-09-30
MA26468A1 (fr) 2004-12-20
NO993658D0 (no) 1999-07-28
OA11079A (en) 2002-03-14
KR20000070541A (ko) 2000-11-25
DK1270565T3 (da) 2004-10-04
ATE242208T1 (de) 2003-06-15
AP9801190A0 (en) 1998-03-31
DE69729762D1 (de) 2004-08-05
TNSN98017A1 (fr) 2005-03-15
JP3573757B2 (ja) 2004-10-06
CN1245490A (zh) 2000-02-23
CA2279186C (en) 2004-02-24
DZ2407A1 (fr) 2003-01-04
CN1127479C (zh) 2003-11-12
PT964849E (pt) 2003-08-29
US6166064A (en) 2000-12-26
NZ336248A (en) 2000-10-27
DE69722663T2 (de) 2004-04-29
CZ257599A3 (cs) 2000-09-13
PE57898A1 (es) 1999-06-11
CO4920230A1 (es) 2000-05-29
WO1998032733A1 (en) 1998-07-30
AP929A (en) 2001-01-18
ZA98685B (en) 1999-07-29

Similar Documents

Publication Publication Date Title
DE69722663D1 (de) Sulfonylharnstoff-derivate und ihre verwendung in der kontrolle der interleukin-1-aktivität
DE69528342D1 (de) Teilchenförmige Schaumkontrollmittel und ihre Verwendung
ATE205714T1 (de) Sulfonamide und ihre verwendung
DE59903869D1 (de) Verwendung von nanoskaligen sterolen und sterolestern
DE69826662D1 (de) 4-brom or 4-iod-phenylamino-benzhydroxamsäurederivate und ihre anwendung als mek-inhibitoren
DE59809178D1 (de) Doppelseitiges Klebeband und seine Verwendung
ATE299503T1 (de) Pyridin-3-carbonsäurederivate und ihre verwendung als zwischenprodukte
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
DE69829955D1 (de) Salze von perfluorierten sulfonen und ihre verwendung als ionisch leitfähige materialien
DE59710579D1 (de) Sulfonyl-mercapto-triazolyl-derivate und ihre verwendung als mikrobizide
DE59802439D1 (de) Spiroverbindungen und deren verwendung
DE59806989D1 (de) Laseretiketten und ihre Verwendung
DE69716062D1 (de) Benzofuran-derivate und deren verwendung
DE69821629D1 (de) Kombinationen von cytokine mit neurotropen aktivität
DE59805492D1 (de) Laseretiketten und ihre Verwendung
DE59603788D1 (de) 1-fluorisochinolinderivate und ihre verwendung in flüssigkristallinen mischungen
ATE196294T1 (de) Piperazin-derivate und ihre verwendung als 5-ht1a-antagoniste
DE69510228D1 (de) Piperidinessigsäurederivate und ihre verwendung als fibrinogenantagonistmittel
DE69902387D1 (de) Oxadiazolinderivate und ihre verwendung als insektizide
DE59603790D1 (de) Trifluortetrahydroisochinolin-derivate und ihre verwendung in flüssigkristallinen mischungen
DE59810405D1 (de) Spiroverbindungen und deren verwendung
DE59603787D1 (de) 1-fluor-6,7-dihydro-5h-isochinolin-8-on-derivate und ihre verwendung in flüssigkristallinen mischungen
DE69728938D1 (de) Peptidantagonisten der zellulären mitogenese und motogenese und deren therapeutische verwendung
DE69719658D1 (de) Dihyropyridazinon- und pyridazinonderivate und ihre verwendung als insektizide und fungizide
DE69801266D1 (de) Diazoniumionen enthaltende Reagentien und ihre Verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee